Uveitis Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018

Veröffentlicht von: precision business insights
Veröffentlicht am: 28.03.2018 07:41
Rubrik: Gesundheit & Medizin


(Presseportal openBroadcast) - Uveitis Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018

Pressekontakt:

Uveitis Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018

Uveitis Pipeline Drugs Assessment

Overview:
Uveitis refers to the inflammation of uvea which is the middle layer of the eyeball. This may occur from either infectious or non-infectious cause. Retina is the sensitive part of the eye, uvea supplies blood to retina. Usually, uveitis is not serious, but if it is untreated may lead to vision loss. Symptoms may include, redness of eye, pain, dark floating spots on vision, blurred vision and others.
There are many possible causes for uveitis including, entry of toxic substances and autoimmune diseases also lead to uveitis. Diagnosis is through the normal eye examination and treatment is given for the underlying diseases if any. Usually, corticosteroid eye drops are suggested to fight against the inflammation. Further, if not work oral or parenteral drugs may be given.

A sample of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/uveitis-pipeline-drugs-assessment/#ulp-4H8Z4LpNMLEuOnnx


Segmentation:
By route of administration, Uveitis pipeline drugs are segmented into
• Oral
• Topical
• Parenteral
By Trial Phase, Uveitis pipeline drugs are segmented as:
• Preclinical Trials
• Phase 1
• Phase 2
• Phase 3
By company, Uveitis pipeline drugs are segmented into
• Apitope International (Ukraine)
• pSivida (U.S.)
• Santen Pharmaceutical Co., Ltd. (Japan)
• Charlesson, LLC. (U.S.)
• Enzo Biochem, Inc. (U.S.)
• Mitotech SA (Luxembourg)
• EyeGate Pharmaceuticals Inc (U.S.)
• Galapagos NV (Belgium)
• Others

To view TOC of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/uveitis-pipeline-drugs-assessment/#ulp-c654SbFYO64MsOhu

Space Analysis:
Various advanced technologies in the molecular and cellular levels are driving the development of uveitis pipeline drugs. Researchers and manufacturing companies are using the various promising targets for uveitis treatment. Targeted therapy found to be more effective in treatment. Other possible targets are to slow the progression of the disease and relieving the symptoms. Many of the companies are collaborating in development of novel therapies for the treatment of uveitis.
• In July 2017, Galapagos announced a new phase II study investigating filgotinib in non-infectious uveitis, being led by filgotinib collaboration partner Gilead Sciences. The phase II study will be a multi-center, randomized, double-masked, placebo-controlled study to assess the safety and efficacy of filgotinib in adult patients with active, non-infectious uveitis.
• In June 2017, pSivida Corp. announced the Company’s second Phase 3 trial of Durasert three-year treatment for posterior segment uveitis achieved the trial’s primary endpoint and results found to be positive.

Need more information about this report @
https://www.precisionbusinessinsights.com/market-reports/uveitis-pipeline-drugs-assessment/#ulp-14mlyhjMGhVjZqa3

Report Description:
Uveitis Disease Pipeline Drugs Assessment report studies the various therapeutics under clinical development for Uveitis treatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the Uveitis disease pipeline drugs development. This report studies the dynamics of the Uveitis Disease Pipeline Drugs i.e. drivers, challenges, and opportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on Uveitis disease pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.

Key Features of the Report:
• Provides the information related to universities and research institutes working in the therapeutics development
• Report comprehensively covers the all active and discontinued studies
• Studies the entire pipeline with special emphasis on companies actively involved in the therapeutics development
• Presents the prominent targets for drug development in each stage of clinical trial
• Provides the in-depth analysis of each drug candidates in the clinical trial phases


Get access to full summary @
https://www.precisionbusinessinsights.com/market-reports/uveitis-pipeline-drugs-assessment/

About Precision Business Insights

Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.

Contact to Precision Business Insights,

Kemp House,
152 – 160 City Road,
London EC1V 2NX

Email: sales@precisionbusinessinsights.com

Toll Free (US): +1-866-598-1553
Website @ https://www.precisionbusinessinsights.com


Bitte beachten Sie, dass für den Inhalt der hier veröffentlichten Meldung nicht openBroadcast verantwortlich ist, sondern der Verfasser der jeweiligen Meldung selbst. AGB | Haftungsausschluss.